Naloxona Accord (Naloxone)

Naloxone works by competitively binding to μ‑opioid receptors in the brain and spinal cord. It displaces opioid molecules without activating the receptors, thereby blocking the opioids' analgesic and respiratory‑depressant actions and allowing normal physiological function to return.

The appropriate dose of Naloxona Accord is determined by the prescribing clinician based on the severity of the opioid exposure, the patient’s clinical condition, and local treatment guidelines. No fixed dosing regimen is provided here.

Safety data for naloxone in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any potential risk to the fetus or infant, and it is typically administered in emergency situations where maternal health is critical.

To order Naloxona Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Naloxona Accord is comparable to other naloxone formulations and to alternative opioid antagonists such as naltrexone. Unlike naltrexone, which is longer‑acting and used for maintenance therapy, naloxone has a rapid onset and short duration, making it the preferred choice for acute overdose reversal.

Naloxona Accord should be stored below 25 °C in its original container, protected from moisture and light. Keep the vial sealed until use and avoid freezing. Follow any additional handling instructions provided with the product label.

Naloxona Accord is administered by intravenous injection. The healthcare professional injects the solution directly into a vein, allowing rapid distribution throughout the bloodstream to counteract opioid effects within minutes.

The most serious risks include precipitating acute opioid withdrawal, which can cause severe agitation, hypertension, or cardiac arrhythmias, as well as rare events such as pulmonary edema, seizures, and anaphylactic reactions. Immediate monitoring after administration is essential.

Naloxona Accord should be avoided in patients with known hypersensitivity to naloxone or any component of the formulation. Caution is advised for individuals with severe cardiovascular disease, as rapid reversal may provoke marked blood‑pressure changes.